OncoMatch/Clinical Trials/NCT06964737
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Is NCT06964737 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Anti-GARP Chimeric Antigen Receptor-T Cells for recurrent malignant glioma.
Treatment: Anti-GARP Chimeric Antigen Receptor-T Cells — This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage III, IV (WHO)
measurable disease by the Radiologic Assessment in Neuro-Oncology (RANO) criteria
Prior therapy
Cannot have received: VEGF inhibitor (bevacizumab)
Subjects must not have received bevacizumab therapy and are not planned to start such therapy
Cannot have received: chemotherapy (temozolomide)
Exception: must stop treatment 14 days prior to undergoing apheresis and remain off therapy throughout the duration of CAR T therapeutic intervention
Patients receiving anti-cancer agents such as chemotherapy (e.g., temozolomide) must stop treatment 14 days prior to undergoing apheresis and remain off therapy throughout the duration of CAR T therapeutic intervention
Lab requirements
Blood counts
white blood cells (wbc) > 4,000 cells/ul; hemoglobin (hgb) > 7 gm/dl; platelets (plt) > 100/dl
Kidney function
serum creatinine ≤ 1.5 x institutional upper limit of normal
Liver function
liver function tests within 1.5 x institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify